@article{3122777,
    title = "Immunogenicity and side-effects of the inactivated hepatitis A vaccine in periodic fever, aphthous stomatitis, pharyngitis, and adenitis patients",
    author = "Maritsi, D.N. and Syrmou, A. and Vartzelis, G. and Diamantopoulos, S. and Tsolia, M.N.",
    journal = "Pediatrics International",
    year = "2019",
    volume = "61",
    number = "1",
    pages = "104-106",
    publisher = "Blackwell Publishing Inc.",
    issn = "1328-8067, 1442-200X",
    doi = "10.1111/ped.13719",
    keywords = "hepatitis A vaccine;  immunoglobulin G;  hepatitis A vaccine;  immunoglobulin G, Article;  child;  clinical article;  cohort analysis;  controlled study;  drug efficacy;  drug safety;  drug tolerability;  female;  fever;  Greece;  hepatitis A;  human;  humoral immunity;  injection site induration;  malaise;  male;  observational study;  pediatrics;  PFAPA syndrome;  priority journal;  prospective study;  seroconversion;  vaccination;  vaccine immunogenicity;  blood;  case control study;  hereditary periodic fever;  immunology;  preschool child, Case-Control Studies;  Child;  Child, Preschool;  Female;  Hepatitis A Vaccines;  Hereditary Autoinflammatory Diseases;  Humans;  Immunity, Humoral;  Immunoglobulin G;  Male;  Prospective Studies",
    abstract = "The aim of this study was to compare the immunogenicity and side-effects of hepatitis A virus (HAV) vaccination between periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) patients and healthy controls who have not been previously exposed to HAV. A prospective observational study was carried out of 28 PFAPA patients and 76 controls who received two doses of the vaccine. Immunogenicity was expressed as seroconversion and seroprotection rates; mean HAV-immunoglobulin G concentration was measured at 0, 1, 7 and 18 months. Side-effects were defined as incidence of adverse events and the effect of vaccination on PFAPA symptoms. All participants were seronegative and seroconverted at 1 month. One month after primary vaccination, 92.9% of PFAPA patients and 77.6% of the controls attained seroprotection, while the rates increased to 100% and 96.1%, respectively, 1 month after the second dose. Seroprotection rates remained adequate 1 year after completion of vaccination. In conclusion, two doses of the inactivated HAV vaccine are well-tolerated and effective in children with PFAPA. © 2019 Japan Pediatric Society"
}